Cargando…

Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

INTRODUCTION: Although advanced gastric cancer has many limitations and response rate is marginal in chemotherapy. Overexpression of human epidermal growth factor receptor 2(HER-2/neu) gene and its protein are associated with increased cell division and a high rate of tumor growth and have been repo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Hai, Cheng, Ying, Piao, Su-Zhou, Xu, Yun-Jie, Sun, Hong-Hua, Cui, Xian, Li, Xiang-Zi, Zhang, Song-Nan, Piao, Long-Zhen, Jin, Yong-Min, Lin, Zhen-hua, Shen, Xiong-Hu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915235/ https://www.ncbi.nlm.nih.gov/pubmed/24472145 http://dx.doi.org/10.1186/1475-2867-14-10

Ejemplares similares

ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor
por: Alvarado, Diego, et al.
Publicado: (2009)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2006)

Why do most c-erbB-2/HER-2-positive breast cancer patients fail to respond to Herceptin?
por: Murphy, ML, et al.
Publicado: (2008)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
por: Schroeder, Richard L., et al.
Publicado: (2014)

Recombinant humanised anti-HER2/neu antibody (Herceptin®) induces cellular death of glioblastomas
por: Mineo, J-F, et al.
Publicado: (2004)

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
por: Montañez-Wiscovich, ME, et al.
Publicado: (2009)

Activation of the Her2/neu receptor leads to antiestrogen resistance, but acquired resistance is not caused by altered ErbB expression and activation
por: Larsen, SS, et al.
Publicado: (2000)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

The Mysterious Ways of ErbB2/HER2 Trafficking
por: Bertelsen, Vibeke, et al.
Publicado: (2014)

3, 3′-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells
por: Ahmad, Aamir, et al.
Publicado: (2013)

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins
por: Smith, B L, et al.
Publicado: (2004)

Prognostic value of ErbB2/HER2 in human meningiomas
por: Arnli, Magnus B., et al.
Publicado: (2018)

Use of the anti HER-2/neu antibody Herceptin in the treatment of human breast cancer: biological rationale and clinical results
por: Slamon, DJ
Publicado: (2000)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Structural basis for the oncogenic signalling complex formed by Grb2 and Gab2 in Her2 (ErbB2/Neu)-driven breast cancers and CML cells
por: Tsirka, T, et al.
Publicado: (2009)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer
por: Schillaci, Roxana, et al.
Publicado: (2012)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer
por: Ortega-Cava, Cesar F., et al.
Publicado: (2011)

Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling
por: Shaw, Greg, et al.
Publicado: (2008)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma
por: Plum, Patrick Sven, et al.
Publicado: (2019)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
por: Goren, D., et al.
Publicado: (1996)

Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells
por: Masuelli, Laura, et al.
Publicado: (2014)

Herceptin-sensitivity of HER2-transgenic mouse mammary tumors
por: Schwall, RH, et al.
Publicado: (2003)

Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis.
por: Børresen, A. L., et al.
Publicado: (1990)

The chemotherapeutic agent bortezomib induces the formation of stress granules
por: Fournier, Marie-Josée, et al.
Publicado: (2010)

Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
por: Doyle, Hester A., et al.
Publicado: (2021)

Association between serum HER2/ErbB2 levels and coronary artery disease: a case–control study
por: Jian, Wen, et al.
Publicado: (2020)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_um4kp9guighvqn9oulpbju2v0k